Emi1 Antibodies

Santa Cruz Biotechnology delivers a wide array of Emi1 monoclonal antibodies for research in cell cycle regulation and checkpoint control. Emi1 monoclonal antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Emi1, or Early mitotic inhibitor 1, plays a crucial role in regulating the cell cycle by inhibiting the activity of the anaphase-promoting complex/cyclosome (APC/C), thereby preventing premature degradation of cyclins and ensuring proper mitotic progression. Understanding Emi1 function is essential for maintaining genomic stability, with significant implications in cancer research, as altered Emi1 expression can lead to uncontrolled cell proliferation. Researchers can explore the complex interactions between Emi1 and its binding partners using specific detection methods. Advanced research techniques allow for detailed examination of Emi1's role in cell cycle progression and mitotic regulation. Investigating Emi1's involvement in various cellular pathways provides insights into potential therapeutic targets. The high specificity and reliability of Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance our understanding of cell cycle regulation and its impact on human health.